Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype.

Chest - 1 Aug 2020

Inoue Yoshikazu, Kaner Robert J, Guiot Julien, Maher Toby M, Tomassetti Sara, Moiseev Sergey, Kuwana Masataka, Brown Kevin K

Abstract excerpt

Biomarkers have the potential to become central to the clinical evaluation and monitoring of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Here we summarize the current understanding of putative serum, BAL fluid, and genetic biomarkers in this setting, according to their hypothesized pathobiologic mechanisms: evidence of epithelial cell dysfunction (eg, Krebs von...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Chronic Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Idiopathic Pulmonary Fibrosis

Share to Lung Diseases, Interstitial

Share to Phenotype

Share to Prognosis

Source

Identifiers

PMID: 32268131
DOI: 10.1016/j.chest.2020.03.037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype.PMID 32268131Read ↗

An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?Semantic proximity Read ↗

Molecular and Genetic Biomarkers in Idiopathic Pulmonary Fibrosis: Where Are We Now?Semantic proximity Read ↗

When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases.Semantic proximity Read ↗

Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.Semantic proximity Read ↗

Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of interstitial lung disease.Semantic proximity Read ↗

Progressive fibrosing interstitial lung disease: prevalence and clinical outcome.Semantic proximity Read ↗

Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype.Semantic proximity Read ↗

Molecular biomarkers in idiopathic pulmonary fibrosis.Semantic proximity Read ↗

Biopsy in interstitial lung disease: specific diagnosis and the identification of the progressive fibrotic phenotype.Semantic proximity Read ↗

The justification for the progressive fibrotic phenotype.Semantic proximity Read ↗

Update on the diagnosis and classification of ILD.Semantic proximity Read ↗

PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.